Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression

NCT03251690 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

246

Enrollment

OTHER

Sponsor class

Conditions

Anti-Retroviral Agents
Efavirenz
HIV-1-infection
Sustained Virologic Response
Dyslipidemias
Rilpivirine

Interventions

DRUG: Tenofovir/Emtricitabine/Rilpivirine
DRUG: Tenofovir/Emtricitabine/Efavirenz

Sponsor

Mahidol University